Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine Inc. (MNMD) is a clinical-stage biotech company pioneering research into psychedelic-inspired therapies for mental health disorders. This dedicated news hub provides investors and researchers with timely updates on MNMD's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases detailing clinical trial progress, partnership announcements with leading research institutions, and analyses of the company's novel approaches to treating conditions like addiction and depression. Our curated collection ensures you stay informed about MNMD's work developing therapies that target neuroplasticity through compounds such as LSD-analogs and psilocybin derivatives.
Key updates include Phase 2 trial results, intellectual property developments, executive leadership changes, and presentations at major medical conferences. All content is sourced from verified channels to maintain compliance with financial disclosure standards.
Bookmark this page for streamlined access to MNMD's evolving story in psychedelic medicine. Check regularly for critical updates about FDA-regulated research programs and breakthrough therapy designation tracking within this emerging biopharmaceutical sector.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced it will host an earnings call on August 11, 2022, at 4:30 p.m. EDT to discuss its financial results for the quarter ended June 30, 2022, alongside a business update. The company focuses on developing innovative products targeting brain health disorders, including psychiatry and addiction. Stakeholders can join the call via telephone or watch the webcast, which will also be archived for 30 days.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its participation in the Canaccord Genuity 42nd Annual Growth Conference, set for August 8-11, 2022, in Boston, MA. The management team will present on August 10 at 11:00 a.m. ET with an in-person format along with investor meetings. A live webcast will be accessible, and a replay will be available for 90 days on their website. MindMed is focused on developing innovative treatments for brain health disorders, targeting critical neurotransmitter systems.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the results of its annual general and special meeting of shareholders held on June 1, 2022. All five management nominees were successfully elected as directors, with percentages of votes ranging from 89.04% to 96.72%. KPMG LLP was appointed as the company's auditor for the coming year. Additionally, shareholders approved an alteration to the company's share structure, eliminating Multiple Voting Shares and re-designating Subordinate Voting Shares as Common Shares. This strategic move aims to streamline the company's capital structure.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its participation in the Jefferies Global Healthcare Conference in New York from June 8-10, 2022. CEO Robert Barrow will present on June 10, 2022, at 12:45 p.m. ET. The event includes an in-person presentation and one-on-one investor meetings. A webcast of the presentation will be available at this link, with a replay for 90 days on MindMed's website. MindMed focuses on developing treatments for brain health disorders.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the appointment of Schond L. Greenway as Chief Financial Officer, effective May 23, 2022. Greenway brings over 20 years of experience in investment banking and corporate advisory, particularly in the life sciences sector. His expertise in US biotech capital markets is expected to advance MindMed's mission of developing innovative therapies for brain health disorders. With numerous near-term milestones ahead, the company aims to enhance its pipeline targeting conditions like anxiety, addiction, and autism.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced positive topline results from its Phase 1 trial of MM-110, a treatment for opioid withdrawal. Conducted on 108 healthy volunteers, the trial demonstrated that MM-110 was well-tolerated, with no serious adverse events reported. The findings support advancing to a Phase 2a trial, set to begin in Q2 2022. The study indicates MM-110's potential in addressing the opioid crisis, focusing on safety, tolerability, and neurocognitive effects. This progress builds on previous studies suggesting the drug's effectiveness in reducing withdrawal symptoms.
Mind Medicine (NASDAQ: MNMD) reported progress in its clinical programs for three lead drug candidates aimed at treating brain health disorders. The company appointed Dr. Francois Lilienthal as Chief Commercial Officer and confirmed a cash balance of $120.5 million as of March 31, 2022, adequate to cover operations into 2024. R&D expenses increased to $10.2 million, while general and administrative expenses rose to $8.3 million. MindMed anticipates multiple upcoming catalysts, including ongoing trials for MM-120, MM-402, and MM-110, which target anxiety, autism, and opioid use disorders respectively.
Mind Medicine (MindMed) (NASDAQ: MNMD) will host a webinar on May 19, 2022, at 11:00am EDT, focusing on substance use disorders and withdrawal management. Presenters include Kelly E. Dunn, PhD, from Johns Hopkins School of Medicine, and Stuart Gitlow, MD, Past President of the American Society of Addiction Medicine. The event will cover the current treatment landscape for opioid use disorder and feature an overview of MindMed's clinical development program for MM-110, aimed at addressing critical gaps in opioid treatment.
MindMed announced positive topline data from a Phase 2 clinical trial at University Hospital Basel evaluating LSD for treating anxiety disorders. Results show significant reductions in anxiety symptoms with 200 µg LSD, featuring a decrease in STAI-G scores from baseline by -16.2 after 16 weeks (p=0.007). The trial, presented on May 11, 2022, indicates that LSD treatment was well-tolerated with minimal adverse effects. These findings support the ongoing clinical development of MM-120 for Generalized Anxiety Disorder, enhancing the company's position in the neuropharmaceutical market.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) will host an earnings call on May 16, 2022, at 8:30 a.m. EDT to discuss its financial results for the quarter ended March 31, 2022. The call aims to provide investors with updates on the company's performance and business developments. MindMed focuses on developing products for brain health, particularly in psychiatry, addiction, pain, and neurology. The company is committed to improving patient outcomes through innovative drug candidates targeting critical neurotransmitter systems.
